Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | CLK3 | P49761 | 1/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.81 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.81 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.81 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.81 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.81 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.81 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.81 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.81 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.81 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.81 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rigosertib SCHEMBL29397572 | 1.00 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498624 | 1.00 | PLK1 (1.00) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498728 | 0.99 | PLK1 (0.98) | PLK1METNQO2FECHCLK3 | |
| Rigosertib SCHEMBL498730 | 0.99 | PLK1 (0.98) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL25053516 | 0.93 | PLK1 (0.87) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL4556188 | 0.93 | PLK1 (0.87) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL6072521 | 0.93 | PLK1 (0.87) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL498447 | 0.92 | PLK1 (0.84) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL498448 | 0.92 | PLK1 (0.84) | PLK1METNQO2FECHCLK3 | |
| SCHEMBL12324480 | 0.92 | PLK1 (0.84) | PLK1METNQO2FECHCLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1721 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122057044-A | Nanometer liposome delivery system for targeting PLK1/Aurora kinase and application thereof in oral squamous cell carcinoma treatment | 徐州医科大学 | 2026-05-19 | — | — | CN | claimed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| US-12616671-B2 | Use of rigosertib to treat RNA virus infections | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-05-05 | — | — | US | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| EP-4729519-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20260092327-A1 | METHODS OF MONITORING MUTATIONS IN TREATMENT OF COLORECTAL CANCER | CARDIFF ONCOLOGY INC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260076970-A1 | CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY INC (US) | 2026-03-19 | — | — | US | claimed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| US-20080161252-A1 | Composition and Methods For the Treatment of Proliferative Diseases | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-07-03 | — | — | US | claimed |
| WO-2008027049-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-06 | — | — | WO | claimed |
| EP-1773353-A2 | FORMULATIONS FOR PARENTERAL ADMINISTRATION OF (E)-2,6-DIALKOXYSTRYRYL 4-SUBSTITUTED BENZYLSULFONES | Onconova Therapeutics, Inc (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006104668-A2 | COMPOSITION AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-10-05 | — | — | WO | claimed |
| EP-1487428-A4 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2006-04-19 | — | — | EP | claimed |
| WO-2006010152-A2 | FORMULATIONS FOR PARENTERAL ADMINISTRATION OF (E)-2,6-DIALKOXYSTRYRYL 4-SUBSTITUTED BENZYLSULFONES | ONCONOVA THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | claimed |
| WO-2005065074-A2 | PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050130942-A1 | Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-06-16 | — | — | US | claimed |
| EP-1487428-A2 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2004-12-22 | — | — | EP | claimed |
| WO-2003072062-A2 | AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-09-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161252-A1 | Composition and Methods For the Treatment of Proliferative Diseases | CCNH, POLH, CCNO | PLK1 196/4885MET 254/4885NQO2 733/4885 |
| US-20260076970-A1 | CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS | PLK1, PLK4, PLK2 | PLK1 1/4885MET 269/4885NQO2 3366/4885 |
| US-12616671-B2 | Use of rigosertib to treat RNA virus infections | EIF2AK2, ACE2, SARS1 | PLK1 91/4885MET 1545/4885NQO2 1273/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | PLK1 68/4885MET 724/4885NQO2 3408/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | PLK1 2636/4885MET 292/4885NQO2 1524/4885 |
| US-20260092327-A1 | METHODS OF MONITORING MUTATIONS IN TREATMENT OF COLORECTAL CANCER | KRAS, HRAS, NRAS | PLK1 25/4885MET 136/4885NQO2 2185/4885 |
| US-20050130942-A1 | Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders | CCNY, CCND2, CCNB1 | PLK1 1376/4885MET 1078/4885NQO2 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.